Subcutaneous trastuzumab was considered non-inferior to intravenous trastuzumab. The incidence of Grade 3–5 adverse events was comparable between the groups, ...

Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study results published ...

SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche ...

Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably varied immune parameters in patients with HER2-positive breast cancer with residual ...

Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC ...

Basel, 23 December 2020– Roche today announced that the European Commission has approved Phesgo ®, a fixed-dose combination of Perjeta ® and Herceptin ® with hyaluronidase, administered by ...

Subcutaneous administration of Herceptin Hylecta resulted in non-inferior levels of trastuzumab in the blood (pharmacokinetics) and non-inferior clinical efficacy (pathological complete response ...

In last two decades, the country’s IP model continues to serve as a global benchmark for balancing innovation with public ...

"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery ...

1 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011 ...